Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Feb 13;19:1451–1467. doi: 10.2147/IJN.S444009

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2024 Li et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

BEC-EVs and BMC-EVs administrations decreased leakage of BECs and increased TJ proteins expression after OGD. (A) Western blotting of ZO-1 and Occludin in OGD-insulted BECs after EVs treatment. (B) Relative quantitative analysis of ZO-1 and Occludin (n=3). (C) Sketch of transwell assay and the relative OGD-insulted BECs monolayer leakage after EVs treatment (n=4). (D) Immunofluorescence staining of ZO-1 and Occludin in OGD-insulted BECs after EVs treatment. Scale bar: 50 µm. (E) Mean fluorescence intensity relative quantification of ZO-1 and Occludin (n=4). ***P < 0.001, **P < 0.01, *P < 0.05.